3 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Financial health
The company holds more cash ($189M) than total debt ($3M).
Operating income covered interest expense -133.1× in the latest year, down from -6.2× 2 years ago.
The company is unprofitable; at its current free-cash-flow burn it has roughly 2.3 years of cash runway.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$9M
-$81M
0.0%
-1031.5%
-29.6%
-27.3%
-$82M
$3M
$189M
2024
$0
-$71M
—
—
-22.0%
-19.8%
-$52M
$9M
$354M
2023
—
-$64M
—
—
36.8%
-246.3%
-$38M
$14M
$22M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Jun '26
$2M
-$26M
0.0%
-1196.8%
-7.0%
-6.6%
-$20M
—
$74M
Mar '26
$3M
-$22M
0.0%
-915.4%
-5.9%
-5.6%
-$24M
—
$242M
Dec '25
$3M
-$26M
0.0%
-923.4%
-9.5%
-8.8%
-$28M
$3M
$189M
Sep '25
$2M
-$20M
0.0%
-1126.6%
-7.3%
-6.6%
-$16M
$4M
$216M
Jun '25
$2M
-$22M
0.0%
-1027.0%
-7.3%
-6.7%
-$20M
$6M
$220M
Mar '25
$1M
-$13M
0.0%
-1133.4%
-4.1%
-3.8%
-$18M
$7M
$257M
Dec '24
$0
-$21M
—
—
-6.5%
-5.9%
-$5M
$9M
$354M
Sep '24
$0
-$23M
—
—
-7.5%
-6.9%
-$15M
$10M
$334M
Jun '24
$0
-$14M
—
—
6.9%
—
-$16M
—
—
Mar '24
—
-$13M
—
—
7.0%
—
-$16M
—
$174M
Dec '23
—
-$21M
—
—
12.1%
-80.8%
-$9M
$14M
$22M
Sep '23
—
-$15M
—
—
9.6%
—
—
—
—
Jun '23
—
-$17M
—
—
12.3%
—
—
—
—
Mar '23
—
-$11M
—
—
9.0%
—
—
—
—
Valuation over time
How the market has priced BIOA against its own fundamentals since 2024-09 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has fallen from 67.5× (Dec '25) to 48.4× (Sep '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is BIOA growing its revenue and profit?
See the revenue and net-income charts above for Bioage Labs, Inc.'s multi-year trend.
How much debt does BIOA have?
As of FY2025, Bioage Labs, Inc. reported $3M of total debt against $189M of cash; operating income covered interest expense -133.1×.
What is BIOA's profit margin?
In FY2025, gross margin was —, operating margin -1031.5%, and net margin -896.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.